ATE462003T1 - Aus wt1 stammende krebsantigenpeptide - Google Patents

Aus wt1 stammende krebsantigenpeptide

Info

Publication number
ATE462003T1
ATE462003T1 AT05727848T AT05727848T ATE462003T1 AT E462003 T1 ATE462003 T1 AT E462003T1 AT 05727848 T AT05727848 T AT 05727848T AT 05727848 T AT05727848 T AT 05727848T AT E462003 T1 ATE462003 T1 AT E462003T1
Authority
AT
Austria
Prior art keywords
peptides derived
cancer antigen
antigen peptides
peptide
cancer
Prior art date
Application number
AT05727848T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE462003T1 publication Critical patent/ATE462003T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT05727848T 2004-03-31 2005-03-30 Aus wt1 stammende krebsantigenpeptide ATE462003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004105219 2004-03-31
PCT/JP2005/006113 WO2005095598A1 (ja) 2004-03-31 2005-03-30 Ｗｔ１由来の癌抗原ペプチド

Publications (1)

Publication Number Publication Date
ATE462003T1 true ATE462003T1 (de) 2010-04-15

Family

ID=35063778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05727848T ATE462003T1 (de) 2004-03-31 2005-03-30 Aus wt1 stammende krebsantigenpeptide

Country Status (11)

Country Link
US (3) US7622119B2 (de)
EP (2) EP1731605B1 (de)
JP (1) JP4886507B2 (de)
AT (1) ATE462003T1 (de)
DE (1) DE602005020121D1 (de)
DK (2) DK2186896T3 (de)
ES (2) ES2556232T3 (de)
PL (1) PL1731605T3 (de)
PT (1) PT1731605E (de)
SI (1) SI1731605T1 (de)
WO (1) WO2005095598A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
US8735357B2 (en) * 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP1584627B1 (de) 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerisiertes peptid
KR101431312B1 (ko) * 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
ES2587980T3 (es) 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
CA2670658A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2009009168A (es) 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
EP3173480A3 (de) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Krebs-antigen-spezifisches t-zell-rezeptorgen, durch das gen codiertes peptid und verwendung davon
EP2216041A4 (de) * 2007-11-20 2012-10-24 Nec Corp Verfahren zur induktion einer zytotoxischen t-zelle, zytotoxischer t-zell-induktor und pharmazeutische zusammensetzung sowie impfstoff mit dem induktor
KR20110053836A (ko) * 2009-11-16 2011-05-24 삼성에스디아이 주식회사 리튬 폴리머 이차 전지
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP2896693A4 (de) 2012-09-12 2016-10-12 Int Inst Cancer Immunology Inc Antigenspezifische helfer-t-zellen-rezeptorgene
WO2014098012A1 (ja) * 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
EP3769782A1 (de) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogene wt-1-peptide und verfahren zur verwendung davon
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
EP2762154A3 (de) 2013-02-05 2015-01-21 Nitto Denko Corporation Impfstoff zur transdermalen Verabreichung
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
IN2014CH00395A (de) 2013-02-05 2015-04-03 Nitto Denko Corp
JP6497691B2 (ja) 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
EP2762152A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1-Peptidkrebsimpfstoffzusammensetzung zur transdermalen Verabreichung
EP3662927A3 (de) 2013-02-05 2020-10-21 Nitto Denko Corporation Impfstoffzusammensetzung
US10023841B2 (en) * 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
CA2974066C (en) 2014-12-25 2025-05-06 International Institute Of Cancer Immunology, Inc. METHOD FOR MODIFYING A T LYMPHOCYTE POPULATION
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
ES2946188T3 (es) 2016-11-09 2023-07-13 Univ Osaka Procedimiento para modificar una población de linfocitos T
US12259379B2 (en) 2017-06-30 2025-03-25 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index
CN112004825A (zh) 2018-02-12 2020-11-27 弗雷德哈钦森癌症研究中心 细胞周期蛋白a1特异性t细胞受体及其用途
CN113784978B (zh) 2019-03-11 2025-07-25 弗雷德哈钦森癌症中心 高亲合力wt1 t细胞受体及其用途
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
CN111978375B (zh) * 2020-08-28 2022-10-04 深圳市乐土生物医药有限公司 具有细胞毒性t细胞诱导能力的蛋白质或多肽
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CN112250752B (zh) * 2020-12-21 2021-03-26 中生康元生物科技(北京)有限公司 肿瘤新抗原表位肽及其应用
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
JP2025525779A (ja) 2022-07-29 2025-08-07 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ATE399179T1 (de) 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
ES2298353T3 (es) * 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) * 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) * 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
EP1584627B1 (de) * 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerisiertes peptid
KR101431312B1 (ko) * 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1

Also Published As

Publication number Publication date
DK1731605T3 (da) 2010-05-25
US8388975B2 (en) 2013-03-05
EP2186896A1 (de) 2010-05-19
EP1731605A1 (de) 2006-12-13
US20130196427A1 (en) 2013-08-01
PL1731605T3 (pl) 2010-08-31
ES2341785T3 (es) 2010-06-28
SI1731605T1 (sl) 2010-07-30
EP1731605A4 (de) 2007-11-07
US20100062013A1 (en) 2010-03-11
WO2005095598A1 (ja) 2005-10-13
PT1731605E (pt) 2010-04-14
HK1144305A1 (en) 2011-02-11
JPWO2005095598A1 (ja) 2008-02-21
DE602005020121D1 (de) 2010-05-06
JP4886507B2 (ja) 2012-02-29
EP1731605B1 (de) 2010-03-24
US20080152631A1 (en) 2008-06-26
US7622119B2 (en) 2009-11-24
DK2186896T3 (en) 2015-12-21
ES2556232T3 (es) 2016-01-14
EP2186896B1 (de) 2015-11-04

Similar Documents

Publication Publication Date Title
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
NO20063624L (no) FC region varianter
ATE428727T1 (de) Neue, an den erythropoietinrezeptor bindende peptide
EA200701825A1 (ru) Вакцины против хламидиоза
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
RU2013119417A (ru) Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
DE602008002810D1 (de) Peptide zur desensibilisierung gegenüber allergenen
WO2007062656A3 (en) A nucleotide vaccine
DE602006020032D1 (de) Il-21-varianten
PL1853305T3 (pl) Szczepionka na bazie peptydu surwiwina
DK1628989T3 (da) Hidtil ukendte, 14- og 15-leddet ring-forbindelser
ITMI20030107A1 (it) Peptidi derivati da rantes.
DE602005007364D1 (de) Peptidcyclisierung
PL1577320T3 (pl) Peptydy pochodzące z ludzkiego białka BPLP, polinukleotydy kodujące te peptydy oraz przeciwciała skierowane przeciw tym peptydom
ATE445634T1 (de) Antimikrobielle peptide
EP2085474A4 (de) Hla bindendes peptid, dessen vorstufe, dafür codierendes dna-fragment und rekombinanter vektor
ATE467643T1 (de) Peptide mit proliferationshemmender wirkung
ITRM20040489A1 (it) Pentraxina lunga ptx3 deglicosilata o desialidata.
ITMO20030076A0 (it) Valvola di frenatura perfezionata.
WO2009130612A3 (en) Prion epitopes and methods of use thereof
EP2066356A4 (de) Neue p. falciparum-impfstoff-proteine und codiersequenzen
ITRM20050128A1 (it) Peptidi immunogeni anti-tumorali e relativi vaccini.
CY1116106T1 (el) Μεθοδος προληψης ή θεραπεια μολυνσης m. tuberculosis
ES1059941Y (es) Rodapie o zocalo calefactor.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1731605

Country of ref document: EP